Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the

Felice Gragnano1, Alessandro Spirito, Noé Corpataux

  • 1Department of Cardiology, Inselspital, Bern University Hospital, Bern, Switzerland.

Insights

Patients presenting with acute coronary syndrome (ACS) face a higher risk of major bleeding after percutaneous coronary intervention (PCI). The Academic Research Consortium (ARC) High Bleeding Risk (HBR) criteria showed lower accuracy in ACS patients.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Clinical Risk Stratification

Background:

  • Identifying bleeding risk factors is crucial for managing patients undergoing percutaneous coronary intervention (PCI).
  • The impact of clinical presentation on post-PCI bleeding risk remains unclear.

Purpose of the Study:

  • To determine if clinical presentation influences bleeding risk in PCI patients.
  • To evaluate the consistent performance of Academic Research Consortium (ARC) High Bleeding Risk (HBR) criteria in acute (ACS) and chronic (CCS) coronary syndrome.

Main Methods:

  • Analysis of consecutive patients from the Bern PCI Registry.
  • Stratification by clinical presentation (ACS vs. CCS).
  • Comparison of one-year bleeding events and assessment of ARC-HBR criteria performance.

Main Results:

  • Among 16,821 patients, ACS presentation was associated with a higher one-year risk of BARC 3 or 5 bleeding (4.97% vs. 3.60%).
  • Adjusted analysis confirmed ACS as a predictor of increased bleeding risk, primarily non-access site-related and within 30 days.
  • ARC-HBR criteria demonstrated lower discrimination in ACS patients compared to CCS patients.

Conclusions:

  • Acute coronary syndrome presentation independently predicts one-year major bleeding risk following PCI.
  • The ARC-HBR score's predictive performance is diminished in ACS patients.
  • Incorporating ACS as a minor criterion may improve the ARC-HBR score's utility.
Abstract

Related Concept Videos

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
102
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
69
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
204
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
216
SBAR II: Application of SBAR01:14

SBAR II: Application of SBAR

SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
5.2K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
84